Tom Powles, Professor at the University of London and Director of Barts Cancer Centre, shared a post on X:
“Uromigos unsung prostate cancer hero ASC025 – David Olmos – 50% 8 year OS for M1 1st line disease – but subgroups (PSMA+ve and BRCA) still have less good outcomes.
Opportunities for further therapy here with PARPi and LuPSMA (+ve PSMA addition and amplitude studies).”
Tom Powles shared findings from ASC025, citing a 50% 8-year overall survival in first-line metastatic prostate cancer. He noted poorer outcomes in PSMA-positive and BRCA subgroups, pointing to PARP inhibitors and LuPSMA as avenues for further therapeutic development.
More posts featuring Tom Powles.